Objective: To determine risk factors of survival outcomes in patients with cervical cancer of Stage IB treated with standard hysterectomy (RH). Materials Methods: From February 2001 to November 2015, patients with cervical cancer of FIGO Stage IB were included, if they received RH of Class III or Type C1. Epidemiological and clinic-pathologic characteristics were compared to determine risk factors of overall survival (OS) and progression free survival (PFS). Results: Among 406 patients included, 371 (91.4%) had definite survival data, with recurrence rate and mortality of 17.2% and 9.4%. After a median follow-up of 48.5 (range 12-189) months, and ten-year PFS were 80% and 73%, and five- and ten-year OS were 88% and 84%, respectively. In multivariate analysis, patients with Stage IB2 (HR 2.0, 95% CI 1.2-3.2), positive vaginal margin (HR 9.2, 95% CI 2.6-33.0), or lymphatic metastasis (HR 2.0, 95% CI 1.1-3.6) had higher recurrence; patients with RH before year of 2011 (HR 2.8, 95% 1.3-6.0), Stage IB2 (HR 3.6, 95% CI 1.9-6.9) or lymphatic metastasis (HR 3.6, 95% CI 1.8-7.1) had higher mortality. Recurrent sites or post-recurrent treatment plans had no impact on the survival after recurrence. Conclusion: The prognosis of cervical cancer patients treated with RH by experienced physicians is favorable. Pathologic characters and experiences of surgeons are predictive factors of survival outcomes.
Cite this article
Survival outcomes of Stage IB cervical cancer treated with standard radical hysterectomy
1 Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Beijing, China
Eur. J. Gynaecol. Oncol. 2019 , 40(5), 810–814; https://doi.org/10.12892/ejgo4754.2019
Published: 10 October 2019